The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Research Report 2024
Synopsis
Devic’s syndrome is also known as neuromyelitis optica which is a central nervous system disorder that specifically affects eye nerves and spinal cord.
The global Devic’s Syndrome (Neuromyelitis Optica) Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Devic’s Syndrome (Neuromyelitis Optica) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Devic’s Syndrome (Neuromyelitis Optica) Treatment.
Report Scope
The Devic’s Syndrome (Neuromyelitis Optica) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Devic’s Syndrome (Neuromyelitis Optica) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alexion Pharmaceuticals, Inc.
Teva Pharmaceuticals
Fresenius Kabi AG
Pharmacia & Upjohn (a subsidary of Pfizer)
Lupin Ltd.
Sagent Pharmaceuticals, Inc.
Zydus Pharmaceuticals, Inc.
Sandoz Inc. (Novartis)
Alkem Laboratories Ltd.
Mylan Pharmaceuticals, Inc.
Hoffmann-La Roche/ Chugai Pharmaceutical
MedImmune LLC
RemeGen, Ltd.
Segment by Type
Eculizumab
Methylprednisolone
Azathioprine
Mycophenolate Mofetil
Rituximab
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Devic’s Syndrome (Neuromyelitis Optica) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Devic’s syndrome is also known as neuromyelitis optica which is a central nervous system disorder that specifically affects eye nerves and spinal cord.
The global Devic’s Syndrome (Neuromyelitis Optica) Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Devic’s Syndrome (Neuromyelitis Optica) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Devic’s Syndrome (Neuromyelitis Optica) Treatment.
Report Scope
The Devic’s Syndrome (Neuromyelitis Optica) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Devic’s Syndrome (Neuromyelitis Optica) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alexion Pharmaceuticals, Inc.
Teva Pharmaceuticals
Fresenius Kabi AG
Pharmacia & Upjohn (a subsidary of Pfizer)
Lupin Ltd.
Sagent Pharmaceuticals, Inc.
Zydus Pharmaceuticals, Inc.
Sandoz Inc. (Novartis)
Alkem Laboratories Ltd.
Mylan Pharmaceuticals, Inc.
Hoffmann-La Roche/ Chugai Pharmaceutical
MedImmune LLC
RemeGen, Ltd.
Segment by Type
Eculizumab
Methylprednisolone
Azathioprine
Mycophenolate Mofetil
Rituximab
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Devic’s Syndrome (Neuromyelitis Optica) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Eculizumab
1.2.3 Methylprednisolone
1.2.4 Azathioprine
1.2.5 Mycophenolate Mofetil
1.2.6 Rituximab
1.3 Market by Application
1.3.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Perspective (2019-2030)
2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Growth Trends by Region
2.2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Region (2019-2024)
2.2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Region (2025-2030)
2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Dynamics
2.3.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Industry Trends
2.3.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Drivers
2.3.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Challenges
2.3.4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Revenue
3.1.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Revenue (2019-2024)
3.1.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue
3.4 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio
3.4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue in 2023
3.5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players Head office and Area Served
3.6 Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Product Solution and Service
3.7 Date of Enter into Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Type
4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Type (2019-2024)
4.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2025-2030)
5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Application
5.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Application (2019-2024)
5.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2019-2030)
6.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024)
6.4 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2019-2030)
7.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024)
7.4 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2019-2030)
8.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2019-2030)
9.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024)
9.4 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2019-2030)
10.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alexion Pharmaceuticals, Inc.
11.1.1 Alexion Pharmaceuticals, Inc. Company Detail
11.1.2 Alexion Pharmaceuticals, Inc. Business Overview
11.1.3 Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.1.4 Alexion Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.1.5 Alexion Pharmaceuticals, Inc. Recent Development
11.2 Teva Pharmaceuticals
11.2.1 Teva Pharmaceuticals Company Detail
11.2.2 Teva Pharmaceuticals Business Overview
11.2.3 Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.2.4 Teva Pharmaceuticals Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.2.5 Teva Pharmaceuticals Recent Development
11.3 Fresenius Kabi AG
11.3.1 Fresenius Kabi AG Company Detail
11.3.2 Fresenius Kabi AG Business Overview
11.3.3 Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.3.4 Fresenius Kabi AG Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.3.5 Fresenius Kabi AG Recent Development
11.4 Pharmacia & Upjohn (a subsidary of Pfizer)
11.4.1 Pharmacia & Upjohn (a subsidary of Pfizer) Company Detail
11.4.2 Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview
11.4.3 Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.4.4 Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.4.5 Pharmacia & Upjohn (a subsidary of Pfizer) Recent Development
11.5 Lupin Ltd.
11.5.1 Lupin Ltd. Company Detail
11.5.2 Lupin Ltd. Business Overview
11.5.3 Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.5.4 Lupin Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.5.5 Lupin Ltd. Recent Development
11.6 Sagent Pharmaceuticals, Inc.
11.6.1 Sagent Pharmaceuticals, Inc. Company Detail
11.6.2 Sagent Pharmaceuticals, Inc. Business Overview
11.6.3 Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.6.4 Sagent Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.6.5 Sagent Pharmaceuticals, Inc. Recent Development
11.7 Zydus Pharmaceuticals, Inc.
11.7.1 Zydus Pharmaceuticals, Inc. Company Detail
11.7.2 Zydus Pharmaceuticals, Inc. Business Overview
11.7.3 Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.7.4 Zydus Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.7.5 Zydus Pharmaceuticals, Inc. Recent Development
11.8 Sandoz Inc. (Novartis)
11.8.1 Sandoz Inc. (Novartis) Company Detail
11.8.2 Sandoz Inc. (Novartis) Business Overview
11.8.3 Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.8.4 Sandoz Inc. (Novartis) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.8.5 Sandoz Inc. (Novartis) Recent Development
11.9 Alkem Laboratories Ltd.
11.9.1 Alkem Laboratories Ltd. Company Detail
11.9.2 Alkem Laboratories Ltd. Business Overview
11.9.3 Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.9.4 Alkem Laboratories Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.9.5 Alkem Laboratories Ltd. Recent Development
11.10 Mylan Pharmaceuticals, Inc.
11.10.1 Mylan Pharmaceuticals, Inc. Company Detail
11.10.2 Mylan Pharmaceuticals, Inc. Business Overview
11.10.3 Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.10.4 Mylan Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.10.5 Mylan Pharmaceuticals, Inc. Recent Development
11.11 Hoffmann-La Roche/ Chugai Pharmaceutical
11.11.1 Hoffmann-La Roche/ Chugai Pharmaceutical Company Detail
11.11.2 Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview
11.11.3 Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.11.4 Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.11.5 Hoffmann-La Roche/ Chugai Pharmaceutical Recent Development
11.12 MedImmune LLC
11.12.1 MedImmune LLC Company Detail
11.12.2 MedImmune LLC Business Overview
11.12.3 MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.12.4 MedImmune LLC Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.12.5 MedImmune LLC Recent Development
11.13 RemeGen, Ltd.
11.13.1 RemeGen, Ltd. Company Detail
11.13.2 RemeGen, Ltd. Business Overview
11.13.3 RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.13.4 RemeGen, Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.13.5 RemeGen, Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
